Arcutis Biotherapeutics (ARQT) said Tuesday that the US Food and Drug Administration has accepted its supplemental new drug application for Zoryve foam 0.3% to treat adults and adolescents aged 12 and older with scalp and body psoriasis.
The FDA has set a Prescription Drug User Fee Act target action date of May 22, 2025, the commercial-stage company said.
The sNDA is backed by positive data from Arcutis' pivotal late-stage trial, a phase 2b study, as well as long-term efficacy and safety data generated from the Zoryve cream development program in plaque psoriasis, the company said.
Price: 9.67, Change: +0.04, Percent Change: +0.42
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.